E75.11 Mucolipidosis IV

Name of the Condition

• Mucolipidosis IV (ICD-10 Code: E75.11)

Summary

Mucolipidosis IV is a rare inherited lysosomal storage disorder characterized by the abnormal accumulation of lipids and mucopolysaccharides in cells. This buildup disrupts cellular function, particularly affecting the nervous system, eyes, and other tissues. The condition is part of a broader category of sphingolipid metabolism disorders and presents with progressive neurological and ocular manifestations.

Causes

The disorder results from genetic mutations in the MCOLN1 gene, which impairs the function of the mucolipin-1 protein. This protein is involved in lysosomal function and calcium homeostasis. The mutations lead to the abnormal storage of lipids and mucopolysaccharides in tissues. Inheritance is autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of mucolipidosis IV or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies for the MCOLN1 mutation.

Symptoms

• Developmental delay or regression, particularly affecting motor skills.
• Corneal clouding or opacity, leading to visual impairment.
• Hypotonia (low muscle tone) or spasticity.
• Intellectual disability or cognitive impairment.
• Speech and language delays.
• Abnormal eye movements or strabismus.

Diagnosis

Diagnosis is based on clinical evaluation, including assessment of neurological and ocular symptoms. Laboratory tests may show elevated levels of certain substances in urine or blood. Genetic testing confirms the presence of MCOLN1 mutations. Imaging studies, such as MRI, may reveal brain abnormalities. Ophthalmologic exams assess corneal clouding and other eye issues.

Treatment Options

There is no cure for mucolipidosis IV. Treatment focuses on managing symptoms and improving quality of life. This may include physical therapy to address motor delays, speech therapy for communication, and visual aids for eye problems. Seizures, if present, are treated with anticonvulsant medications. Regular monitoring by a multidisciplinary team is recommended.

Prognosis and Follow-Up

Prognosis varies, but most individuals experience progressive neurological decline and visual impairment. Life expectancy may be reduced, though some individuals live into adulthood. Regular follow-up with neurologists, ophthalmologists, and other specialists is essential to manage symptoms and address complications. Early intervention can help optimize function and quality of life.

Complications

• Progressive vision loss due to corneal clouding or retinal degeneration.
• Severe motor impairment or loss of ambulation.
• Intellectual disability or cognitive decline.
• Seizures or other neurological complications.
• Feeding difficulties or gastrointestinal issues.

Lifestyle & Prevention

• Genetic counseling for families with a history of the disorder.
• Early intervention services (e.g., physical, occupational, speech therapy) to support development.
• Regular eye exams to monitor and address visual changes.
• Adaptive equipment or assistive devices to aid mobility and daily activities.

When to Seek Professional Help

Seek medical attention if there are signs of developmental delay, vision problems, or neurological symptoms. Prompt evaluation is important for early diagnosis and intervention. Consult a healthcare provider if symptoms worsen or new complications arise.

Tips for Medical Coders

When coding for mucolipidosis IV, use the specific ICD-10-CM code E75.11. Ensure documentation supports the diagnosis, including clinical findings, genetic testing results, and any associated complications. Verify that the code aligns with the patient’s confirmed diagnosis and documented symptoms. Avoid using unspecified codes unless the diagnosis is not yet confirmed.